ULTRA-RARE CANCERPediatric Brain TumorWHO 5th Edition Classification

Diffuse Intrinsic Pontine Glioma (DIPG)

Ultra-Rare Malignancy (< 1 case per 1,000,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A highly aggressive tumour that grows within the pons, the part of the brainstem controlling breathing, swallowing, eye movement and balance. Because it infiltrates rather than forms a removable lump, surgery is not an option. Under the current WHO classification it is grouped as diffuse midline glioma, H3 K27-altered, CNS WHO grade 4.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Rapidly progressive cranial nerve palsy in a child
  • New swallowing difficulty with aspiration
Who It Affects

Children, peak age 5-9 years; no strong sex predilection

Annual Incidence

Approximately 2-3 per million children per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Double vision or an eye that will not turn outward
Facial droop or asymmetric smile
Unsteady walking, frequent falls
Difficulty swallowing or a change in speech
Morning headache with vomiting (raised pressure)

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

H3F3A K27MHIST1H3B K27MACVR1TP53PPM1D

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Focal radiotherapy (54 Gy) - the only treatment with proven benefit

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Re-irradiation at progression in selected children

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Clinical trials (ONC201/dordaviprone, CAR-T, convection-enhanced delivery)

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Corticosteroids for symptom control

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Early integrated palliative and family support

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Poor. Median survival is approximately 9-12 months from diagnosis, and long-term survival beyond two years is uncommon. Radiotherapy usually produces several months of meaningful symptom improvement.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

ONC201 (dordaviprone) in H3 K27M-altered glioma, GD2-directed CAR-T cell therapy, and convection-enhanced delivery to bypass the blood-brain barrier are the most active lines of investigation.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Diffuse Intrinsic Pontine Glioma

Browse All Oncologists

Dr. Mark M. Souweidane

Pediatric Neurosurgeon, Vice Chair of Neurological Surgery

30+ yrs exp

Weill Cornell Medicine / NewYork-Presbyterian Hospital

New York, USA

Pediatric brain tumorsBrainstem tumorsDIPG
Vetted DirectoryConsult Specialist

Dr. Enrica Tan

Senior Consultant, Pediatric Oncologist

15+ yrs exp

KK Women’s and Children’s Hospital (KKH)

Singapore, Singapore

Pediatric neuro-oncologyBrain tumorsDIPG
Vetted DirectoryConsult Specialist

Dr. Jacques Grill

Head, Pediatric Brain Tumor Program

20+ yrs exp

Gustave Roussy Cancer Campus

Paris, France

Pediatric brain tumorsDIPGClinical trials
Vetted DirectoryConsult Specialist

Dr. Rakesh Jalali

Radiation Oncologist, Medical Director

28+ yrs exp

Apollo Proton Cancer Centre

Chennai, India

Pediatric brain tumorsProton therapyDIPG
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

ultra-rare

Malignant Rhabdoid Tumor

ultra-rare

Hepatosplenic T-cell Lymphoma (HSTCL)

ultra-rare

T-cell Prolymphocytic Leukemia (T-PLL)

ultra-rare

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Independent Tumor Board Review

Facing a Diagnosis of Diffuse Intrinsic Pontine Glioma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult